BLU Share Price

Open 0.26 Change Price %
High 0.26 1 Day -0.02 -7.69
Low 0.24 1 Week -0.03 -11.11
Close 0.24 1 Month -0.04 -14.29
Volume 256020 1 Year -0.91 -79.13
52 Week High 2.99
52 Week Low 0.20
BLU Important Levels
Resistance 2 0.26
Resistance 1 0.25
Pivot 0.25
Support 1 0.23
Support 2 0.22
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
ENB 54.26 -0.88%
ENB 54.26 -0.88%
ENB 54.26 -0.88%
ENB 54.26 -0.88%
TBE 0.03 0.00%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
I 3.37 19.93%
CUM 0.90 13.92%
CUM 0.90 13.92%
ESP 2.53 10.96%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
RKN 1.00 -16.67%
RKN 1.00 -16.67%
IMP 0.10 -16.67%
IMP 0.10 -16.67%
IMP 0.10 -16.67%
ANX 0.07 -12.50%
ANX 0.07 -12.50%
GCL 1.28 -12.33%
GCL 1.28 -12.33%
More..

BELLUS Health, Inc. (TSE: BLU)

BLU Technical Analysis 5
As on 24th Feb 2017 BLU Share Price closed @ 0.24 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.74 & Strong Sell for SHORT-TERM with Stoploss of 0.27 we also expect STOCK to react on Following IMPORTANT LEVELS.
BLU Target for February
1st Target up-side 0.29
2nd Target up-side 0.3
3rd Target up-side 0.31
1st Target down-side 0.25
2nd Target down-side 0.24
3rd Target down-side 0.23
BLU Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.bellushealth.com
BLU Address
BLU
275 Armand-Frappier Boulevard
Laval, QC H7V 4A7
Canada
Phone: 450-680-4500
Fax: 450-680-4501
BLU Latest News
Bellus Health Announces Payment to Thallion CVR Holders   Montreal Gazette   - 18th Feb 17
BELLUS Health provides update on pipeline   Canada NewsWire (press release)   - 21st Dec 16
Bellus Health: Phase 3 Results of Kiacta for AA Amyloidosis   Drug Discovery & Development   - 21st Jun 16
Bellus Health Plummets After Protein-Fighting Drug Fails Test   Bloomberg   - 20th Jun 16
Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 ...   GlobeNewswire (press release)   - 21st Jan 16
BELLUS Health: Results From KIACTA Phase 3 Clinical Trial Expected In Mid-2016   Seeking Alpha   - 18th Nov 15
Bellus Health Developing Shigamab For The Treatment Of STEC-HUS   Seeking Alpha   - 07th Oct 15
Auven Therapeutics and Bellus Health Announce Completion of Enrollment in the ...   Business Wire (press release)   - 28th May 14
Auven Therapeutics and BELLUS Health Announce Engagement of Financial Advisor ...   Business Wire (press release)   - 07th May 14
BELLUS Health to acquire Thallion Pharmaceuticals   Canada NewsWire (press release)   - 18th Jun 13
Interactive Technical Analysis Chart BELLUS Health, Inc. ( BLU TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on BELLUS Health, Inc.
BLU Business Profile
BELLUS Health Inc., together with its subsidiaries, focuses on the research and development of pharmaceutical drug candidates. The company’s lead program is KIACTA, which is in Phase III clinical trial for the treatment of AA amyloidosis. Its clinical stage drug candidate is Shigamab, a monoclonal antibody therapy for the treatment of hemolytic uremic syndrome related to shiga toxin-producing E. coli bacterial infections. The company also has an agreement with AmorChem Holdings Inc. to develop drug candidates for the treatment of AL amyloidosis. It has a strategic partnership with Auven Therapeutics for the development of KIACTA and Pharmascience. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.